PolyPeptide Group AG shareholders approved all proposals put forward by the board of directors at an extraordinary general meeting, including the election of five new board members and the removal of long-standing transfer and voting restrictions, according to a company announcement. The decisions are contingent on the settlement of a public tender offer by Samsung Peptide AG, a wholly owned subsidiary of Samsung Biologics Co., Ltd., for all publicly held registered shares of PolyPeptide. The outcome marks a decisive step toward the company’s integration into the Samsung Biologics fold and carries significant implications for the peptide-based contract development and manufacturing organization (CDMO) sector.
Shareholders elected John Chongbo Rim, Seungho Ryu, Cheol Woo Ryu, Mihyun Yang and Joonkyung Seong as board members for a term ending at the conclusion of the next annual general meeting. John Chongbo Rim was elected chair of the board, while Cheol Woo Ryu and Seungho Ryu were elected to the Remuneration and Nomination Committee. All elections are subject to and effective as of the settlement of the tender offer. The shareholders also resolved, subject to the satisfaction or waiver of all offer conditions in the offer prospectus dated 31 August 2026, to remove the transfer restrictions and voting limitations from PolyPeptide’s articles of association. The removal of these provisions, known as Vinkulierung and Stimmrechtsbeschränkungen, eliminates structural barriers that could have impeded the acquisition and full exercise of shareholder rights.
The approvals matter because they effectively dismantle the defensive mechanisms that often complicate takeovers of Swiss-listed companies. By agreeing to remove the transfer restrictions and voting limits, shareholders have paved the way for Samsung Biologics to consolidate its ownership and exercise full control over PolyPeptide without the constraints that typically apply to registered shares. This is particularly significant given PolyPeptide’s role as a specialized global CDMO for peptide-based active pharmaceutical ingredients, with a broad portfolio that includes significant exposure to metabolic diseases such as GLP-1 therapies. The company operates a network of six GMP-certified facilities across Europe, the U.S. and India and traces its history back to 1952.
The new board’s composition signals a clear shift in governance toward Samsung Biologics’ leadership. John Chongbo Rim’s appointment as chair, alongside the election of Seungho Ryu and Cheol Woo Ryu to the Remuneration and Nomination Committee, suggests that the incoming majority owner intends to move swiftly to align PolyPeptide’s strategy and oversight with its own corporate priorities. For investors, the outcome reduces uncertainty around the tender offer, as the board reshuffle and the removal of restrictions were among the key conditions for closing. PolyPeptide’s shares are listed on SIX Swiss Exchange under the ticker PPGN, and the company provides products and services from pre-pre-clinical to commercial stages.
Additional details are available in the PolyPeptide_EGM Results 2026_ENG document and the original release on www.newmediawire.com, as distributed by NEWMEDIAWIRE. The company’s website is polypeptide.com.
